# Disc Medicine (IRON) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IRON
## Company Profile
- Ticker: IRON
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Hematology
## Stock Data
- Close: 80.59 USD
- Market cap: 2597538052 USD
- Last updated: 2026-08-12
## Business Overview
### Hematology Drug Development
Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease.
### Bitopertin in EPP
Bitopertin is being evaluated in the Phase 3 APOLLO trial for erythropoietic protoporphyria, a disorder caused by accumulation of phototoxic protoporphyrin. The program has completed enrollment and is intended to support a response to an earlier FDA complete response letter.
### DISC-0974 for Anemia
DISC-0974 is an investigational anti-hemojuvelin therapy designed to suppress hepcidin and improve iron availability. It is being studied in the Phase 2 RALLY-MF trial for anemia of myelofibrosis and in a separate Phase 2 study for anemia associated with inflammatory bowel disease.
### DISC-3405
DISC-3405 is a monoclonal antibody targeting transferrin receptor 1. The candidate is in Phase 2 development for polycythemia vera and Phase 1b development for sickle cell disease, extending Disc’s approach to disorders of red-cell production and function.
## Why The Stock Is Moving

As of Aug 12, 2026, IRON closed down 0.76% at $80.59. No new same-company headline was identified in the current news window.

## Future Catalysts

- Updated RALLY-MF Phase 2 data for DISC-0974 to be presented at ASCO in June 2026.
- Topline results from the Phase 3 APOLLO trial of bitopertin expected in the fourth quarter of 2026.
- Topline RALLY-MF results and an end-of-Phase 2 FDA meeting expected by year-end 2026.
- Initial data from DISC-3405 studies in polycythemia vera and sickle cell disease expected in the fourth quarter of 2026.
- Response to the bitopertin complete response letter following APOLLO, with an FDA decision expected by mid-2027.
- Initial Phase 2 data for DISC-0974 in inflammatory bowel disease expected in 2027.

## Recent News
- 2026-07-30 12:30 EST — [Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/IRON/disc-medicine-reports-second-quarter-2026-financial-results-and-provides-busines-ab5a4d9e) — Source: Disc Medicine
- 2026-06-12 12:30 EST — [Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-3a623f7d) — Source: Disc Medicine
- 2026-06-09 12:30 EST — [Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria](https://biopharmsignal.com/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-in-erythrop-f5d339d3) — Source: Disc Medicine
- 2026-06-02 12:00 EST — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-01 12:30 EST — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine